Literature DB >> 2495261

The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay.

I J Stratford1, M A Stephens.   

Abstract

We obtained good agreement between the MTT assay and conventional clonogenic assays regarding the concentration and contact time required to produce a given level of killing of Chinese hamster V79 cells treated in either air of N2 with a range of bioreductive cytotoxic drugs. All agents chosen for these experiments represented classes of compounds known to be more toxic towards hypoxic cells than they are to aerobic cells. Namely a quinone, mitomycin C; a di-N-oxide, SR4233; and a number of nitro-heterocyclics including misonidazole. The MTT assay is carried out with V79 cells attached to the bottom of 1 cm glass wells within a 24 well plate. All procedures, that is drug exposure, cell growth, metabolism of MTT are then carried out in situ. To measure optical density we used an ELIZA plate reader modified to take 24-well plates. We propose that this method provides a simple, rapid procedure for evaluating the cytotoxicity of bioreductive drugs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495261     DOI: 10.1016/0360-3016(89)90898-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  22 in total

1.  The kinetics and mechanism of repair of UV induced DNA damage in mammalian cells. The use of 'caged' nucleotides and electroporation to study short time course events in DNA repair.

Authors:  R A Meldrum; W S Meaking; C W Wharton
Journal:  Nucleic Acids Res       Date:  1994-04-11       Impact factor: 16.971

2.  Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.

Authors:  T Shibata; Y Shibamoto; K Sasai; N Oya; R Murata; T Takagi; M Hiraoka; M Takahashi; M Abe
Journal:  Br J Cancer Suppl       Date:  1996-07

3.  The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables.

Authors:  G Nikkhah; J C Tonn; O Hoffmann; H P Kraemer; J L Darling; W Schachenmayr; R Schönmayr
Journal:  J Neurooncol       Date:  1992-05       Impact factor: 4.130

4.  Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer.

Authors:  I F Dennis; J R Ramsay; P Workman; N M Bleehen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 5.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

6.  Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia.

Authors:  T Bando; K Kasahara; K Shibata; Y Numata; U Heki; H Shirasaki; K Iwasa; M Fujimura; T Matsuda
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 7.  Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.

Authors:  J C Bremner
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

8.  Thymidylate synthase as a target enzyme for the melanoma-specific toxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol.

Authors:  J A Prezioso; N Wang; W D Bloomer
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 9.  The experimental development of bioreductive drugs and their role in cancer therapy.

Authors:  P Workman; I J Stratford
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

10.  The anti-cancer effect of COX-2 inhibitors on gastric cancer cells.

Authors:  Soo-Jeong Cho; Nayoung Kim; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.